1. Introduction {#sec1-ijms-17-00508}
===============

Eicosanoids, such as prostaglandins (PGs), leukotrienes (LTs), and a number of hydroxyl and epoxy compounds ([Figure 1](#ijms-17-00508-f001){ref-type="fig"}), are bioactive lipid mediators that play vital roles in physiological and pathophysiological conditions \[[@B1-ijms-17-00508],[@B2-ijms-17-00508]\]. They are key mediators and regulators of inflammation and exert both pro- and anti-inflammatory effects \[[@B3-ijms-17-00508],[@B4-ijms-17-00508],[@B5-ijms-17-00508]\]. Inflammation, a mechanism to protect the host from harmful stimuli, is implicated in the pathogenesis of a number of diseases, including cardiovascular disease, diabetes, allergic diseases, obesity, and cancer \[[@B6-ijms-17-00508],[@B7-ijms-17-00508],[@B8-ijms-17-00508],[@B9-ijms-17-00508],[@B10-ijms-17-00508]\]. Thus, many studies have attempted to identify biomarkers of inflammation, for which the eicosanoids have been targeted as critical metabolites \[[@B11-ijms-17-00508],[@B12-ijms-17-00508]\]. The levels of eicosanoids in biological systems have been assessed to investigate their roles in cell function and pathophysiological events \[[@B13-ijms-17-00508],[@B14-ijms-17-00508]\].

Enzyme-linked immunosorbent assays (ELISAs) are widely used to quantify eicosanoids \[[@B15-ijms-17-00508],[@B16-ijms-17-00508]\]. However, these assays are limited by the lack of commercially available antibodies and their non-specificity. They are also insufficient for multiplex analyses because a large quantity of sample is required to quantify multiple target compounds. For the simultaneous analysis of diverse eicosanoids in a mixture, chromatographic separation using gas chromatography (GC) or liquid chromatography (LC) has been used \[[@B17-ijms-17-00508],[@B18-ijms-17-00508]\]. However, LC is more applicable to analyze various eicosanoids than GC, which requires derivatization to increase the volatility and thermal stability of compounds. Furthermore, ultraviolet (UV) detection lacks sensitivity and is applicable only to a limited number of UV-light-absorbing analytes \[[@B19-ijms-17-00508]\]. Thus, LC coupled to mass spectrometry (MS)-based techniques have been recently used to profile eicosanoids \[[@B20-ijms-17-00508],[@B21-ijms-17-00508],[@B22-ijms-17-00508],[@B23-ijms-17-00508]\]. Ultra-performance LC (UPLC) with a small-particle-size column provides fast and effective separation of various molecules \[[@B24-ijms-17-00508]\]. Multiple reaction monitoring (MRM) based on tandem MS (MS/MS) is also effective for the sensitive and selective profiling of each molecular species \[[@B25-ijms-17-00508]\]. Finally, UPLC-MS/MS is a good tool for the comprehensive profiling of eicosanoids. Such characterization of eicosanoids may provide insight into their correlations with inflammatory conditions.

Macrophages, which are the major source of various lipid mediators, respond to a variety of stimuli by producing various eicosanoids \[[@B26-ijms-17-00508],[@B27-ijms-17-00508]\]. The RAW264.7 murine macrophage cell line has been used in numerous studies as a model of primary macrophages. Lipopolysaccharide (LPS) induces cytokine production and the acute-phase response, and so has been used extensively in mechanistic studies of inflammation \[[@B28-ijms-17-00508],[@B29-ijms-17-00508]\]. In this study, UPLC-MS/MS was used to profile the eicosanoid content of RAW264.7 cells treated with various concentrations of LPS. The degree of cellular inflammation may differ depending on LPS concentration. The objective of this study was to perform a comprehensive profiling of eicosanoids known to be related to inflammation as well as other less known species in inflammatory cells. The characterization of eicosanoids altered in RAW264.7 cells by different levels of inflammation may help elucidate the correlation between inflammation and eicosanoid metabolism.

2. Results {#sec2-ijms-17-00508}
==========

2.1. Effect of Lipopolysaccharide (LPS) on RAW264.7 Cells {#sec2dot1-ijms-17-00508}
---------------------------------------------------------

LPS-stimulated RAW264.7 cells were used to elucidate the correlation between inflammation and eicosanoid metabolism. The cells were treated with 0, 1, 10, 100, 1000 ng/mL LPS for 18 h, and monitored under optical microscopy. LPS is known to induce the differentiation of RAW264.7 cells into dendritic-like cells \[[@B30-ijms-17-00508],[@B31-ijms-17-00508]\]. We observed that LPS-activated RAW264.7 cells had a differentiated form with accelerated spreading and forming pseudopodia ([Figure 2](#ijms-17-00508-f002){ref-type="fig"}). Next, the supernatants were subjected to quantification of nitric oxide (NO) and pro-inflammatory cytokine levels. LPS-induced NO production in RAW264.7 cells changed in a concentration-dependent manner ([Figure 3](#ijms-17-00508-f003){ref-type="fig"}A). NO production by cells treated with 1000 ng/mL LPS was 10-fold greater than that of the control. LPS also induced the secretion of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), by RAW264.7 cells in a concentration-dependent fashion ([Figure 3](#ijms-17-00508-f003){ref-type="fig"}B,C). These results showed that LPS activated inflammatory signaling pathways.

2.2. Profiling of Eicosanoids by Ultra Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (UPLC-MS/MS) {#sec2dot2-ijms-17-00508}
-------------------------------------------------------------------------------------------------------------------------

To profile the eicosanoid levels in RAW264.7 cells, we established a multiple-reaction monitoring (MRM) method based on UPLC-MS/MS. First, several standards, 5-hydroxy-eicosatetraenoic acid-d8 (5(S)HETE-d8), 14,15-epoxy-eicosatrienoic acid-d11 (14,15EET-d11), leukotriene B~4~-d4 (LTB~4~-d4), prostaglandin E~2~-d4 (PGE~2~-d4), prostaglandin D~2~-d4 (PGD~2~-d4), and arachidonic acid-d8 (AA-d8), were used to optimize the analytical conditions. The adduct ion of each eicosanoid was confirmed by MS scans and were detected primarily as \[M ‒ H\]^−^ ions by electropray ionization (ESI) in the negative-ion mode. Previously reported MRM transitions for eicosanoids were employed in the current study \[[@B32-ijms-17-00508]\]. Furthermore, source conditions (source temperature (Temp), nebulizer gas (GS1), heater gas (GS2)) and the compound parameters (collision energy (CE) and declustering potential (DP)) of the mass spectrometer were optimized using eicosanoid standards. [Table 1](#ijms-17-00508-t001){ref-type="table"} shows the MRM transitions (precursor *m*/*z* (Q1) \> product *m*/*z* (Q3)), DP, and CE of the eicosanoid standards. Use of a UPLC system with a small-particle-size column enabled effective separation of these standards within 25 min at a flow rate of 0.5 mL/min ([Figure 4](#ijms-17-00508-f004){ref-type="fig"}).

Next, the performance of eicosanoid analyses based on MRM was validated ([Table 2](#ijms-17-00508-t002){ref-type="table"}). Each eicosanoid standard was analyzed six times and the relative standard deviations (RSDs) (%) were calculated. The RSDs (%) of the relative RTs and the relative peak areas were less than 0.3% and 8%, respectively. This method showed a high degree of reproducibility and the correlation coefficient (*R*^2^) for each eicosanoid analysis was at least 0.9959, indicating a high degree of reliability. The limit of detection (LOD) and the limit of quantification (LOQ) of the eicosanoid standards are also shown. With the exception of 14,15-EET-d11, the LC/MS method exhibited sufficient sensitivity for the standards. Thus, in the analysis of biological samples, a higher concentration of 14,15-EET-d11 was required for its use as an internal standard (IS).

2.3. Quantification of Eicosanoids in LPS-Treated RAW264.7 Cells {#sec2dot3-ijms-17-00508}
----------------------------------------------------------------

The above UPLC/MS/MS-based method was used to quantify eicosanoids in RAW264.7 cells treated with 0, 1, 10, 100, and 1000 ng/mL LPS. Assays were performed in triplicate for each LPS concentration. Eicosanoids were extracted using 10% methanol. In this study, a total of 150 MRM transitions were used to profile eicosanoids. A total of 79 eicosanoids were identified in RAW264.7 cells ([Table 3](#ijms-17-00508-t003){ref-type="table"}). To ensure reliable quantification, we used deuterated compounds, including 5(S)-HETE-d8, 14,15-EET-d11, AA-d8, LTB~4~-d4, and PGE~2~-d4, as ISs to normalize the data. The normalized data (peak areas of compounds/peak area of IS) were subjected to statistical analyses.

First, we applied principal component analysis (PCA) \[[@B33-ijms-17-00508],[@B34-ijms-17-00508]\] to differentiate the RAW264.7 cells treated with various LPS concentrations. This resulted in effective separation in the corresponding PCA score plot ([Figure 5](#ijms-17-00508-f005){ref-type="fig"}). Each point represents an individual sample and the scatter of samples indicates similarities or differences in eicosanoid composition. Samples treated with 0, 1, and 10 ng/mL LPS were scattered on the lower side of the plot and those treated with 100 and 1000 ng/mL LPS were scattered on the upper side. The degree of inflammation increased with increasing LPS concentration. This demonstrated that eicosanoid contents differ depending on the degree of inflammation.

Second, changes in the levels of 79 eicosanoids can be described in a heatmap ([Figure 6](#ijms-17-00508-f006){ref-type="fig"}). This hierarchical clustering enabled effective differentiation of the five groups. Several of the 79 eicosanoid species were upregulated by treatments with 100 and 1000 ng/mL LPS. In contrast, the levels of other eicosanoids decreased with increasing LPS concentration. The levels of still other species were not correlated with LPS concentration. Therefore, up- and down-regulation of eicosanoids were associated with LPS-induced inflammation.

3. Discussion {#sec3-ijms-17-00508}
=============

To evaluate altered eicosanoid metabolism in RAW264.7 cells, we focused on the pathway of eicosanoid synthesis from AA ([Figure 7](#ijms-17-00508-f007){ref-type="fig"}). Several PGs, such as PGD~2~, PGE~2~, and PGF~2α~, are synthesized from AA by cyclooxygenase (COX)-1 and COX-2. Furthermore, 15-HETE is synthesized from AA by 15-lipoxygenase (LOX). In addition, 12-LOX and 5-LOX also synthesize 12-HETE and 5-HETE, respectively, from AA. Our results showed that AA was down-regulated following treatment with high concentrations of LPS. This indicated that AA was used as the substrate to synthesize several eicosanoids. PGE~2~, which plays a pro-inflammatory role \[[@B35-ijms-17-00508],[@B36-ijms-17-00508]\], was upregulated following treatment with high concentrations of LPS. In contrast, two other PGs (PGE~2~ and PGF~2α~) and 15-HETE were upregulated. In addition, 12-HETE was upregulated slightly and 5-HETE was down-regulated following treatments with high concentrations of LPS. Therefore, COX-1, COX-2, and 15-LOX were highly activated by LPS-induced inflammation, whereas 12-LOX was only slightly activated and 5-LOX was suppressed.

Many previous studies have reported the utility of various eicosanoid species as biomarkers for diseases and pathophysiological conditions \[[@B11-ijms-17-00508],[@B37-ijms-17-00508],[@B38-ijms-17-00508],[@B39-ijms-17-00508]\]. For example, the endogenous levels of AA, PGE~2~, and 12-HETE were significantly altered in cancerous mucosae \[[@B40-ijms-17-00508]\]. This indicates that inflammation is correlated with tumorigenesis. Rago *et al.* \[[@B41-ijms-17-00508]\] also reported the quantities of several eicosanoids in human plasma to develop biomarkers to distinguish three groups: healthy individuals, hypertensive patients, and severe atherosclerotic patients. The results showed that lower levels of 8-HETE, LTB4, 9-HODE, and 13-HODE are potential biomarkers for severe heart disease. Eicosanoid metabolism may differ depending on biological samples and pathophysiological events. However, the detailed metabolism of major and minor eicosanoids in human diseases that involve inflammation has yet to be studied.

To characterize eicosanoid metabolism in inflammatory cells, comprehensive profiling of various eicosanoids is required. In this study, we evaluated changes in the levels of not only known eicosanoids related to inflammation but also other, less well-known species. The following 39 eicosanoids were upregulated following treatment with high concentrations of LPS: (1) eicosanoids derived from AA: 9-HETE, 11-HETE, 12-HETE, 15-HETE, 11,12-DHET, 12-HHT, PGA~2~, PGD~2~, PGE~2~, PGF~2α~, dihomo PGD~2~, dihomo PGF~2α~, dihomo PGJ~2~, dihomo 15d PGJ~2~, 15d-PGA~2~, 15d-PGD~2~, 11β dhk PGF~2α~, dhk PGD~2~, dhk PGE~2~, PGK~2~, 15k PGF~2~, and LXB~4~; (2) eicosanoids derived from linoleic acid: 9-HODE, and 13-HODE; (3) eicosanoids derived from eicosapentaenoic acid: 9-HEPE, 11-HEPE, 15-HEPE, 15-oxoEDE, PGD~3~, and PGE~3~; (4) eicosanoids derived from docohexaenoic acid: 11-HDoHE, 13-HDoHE, 16-HDoHE, and 17-HDoHE; (5) eicosanoids derived from gamma-linoleic acid: 13-HOTre-g; and (6) eicosanoids derived from dihomo-gamma-linoleic acid: 15-HETrE, PGD~1~, PGE~1~, and PGF~1α~. The following seven eicosanoids were down-regulated following treatments with high concentrations of LPS: (1) eicosanoids derived from AA: 5-HETE, 5,6-DHET, 5,6-EET, and 11,12-EET; (2) eicosanoids derived from eicosapentaenoic acid: 5-HEPE; and (3) eicosanoids derived from dihomo-gamma-linoleic acid: 5-HETrE. Other eicosanoid species were not influenced by LPA treatment in a concentration-dependent manner.

In conclusion, a profiling method based on UPLC-MS/MS was used to characterize the effect of LPS treatment on eicosanoid metabolism in RAW264.7 cells. The degree of inflammation increased with increasing LPS concentration. A total of 79 eicosanoids were identified in RAW264.7 cells. PCA and heatmap generation were used to differentiate RAW264.7 cells treated with different concentrations of LPS. The five groups were well separated in the PCA score plot, and the heatmap was used to identify the up- or downregulation of eicosanoids according to LPS concentration. To our knowledge, this study is the first attempt to assess the levels of cellular eicosanoids altered by the degree of inflammation. A total of 39 eicosanoids were upregulated, and seven were down-regulated by LPS treatment in a concentration-dependent manner. Our novel UPLC-MS/MS technique has the potential for eicosanoid profiling and evaluating correlations between inflammation and eicosanoid metabolism. The eicosanoids up- or down-regulated by LPS can be applied as typical biomarkers for inflammation. In the future, the levels of inflammation-related eicosanoids in biological samples are needed to estimate their roles in cell function and pathophysiological events.

4. Materials and Methods {#sec4-ijms-17-00508}
========================

4.1. Reagents {#sec4dot1-ijms-17-00508}
-------------

HPLC-grade water, methanol, acetonitrile, and isopropyl alcohol were purchased from J.T. Baker (Avantor Performance Material, Inc., Center Valley, PA, USA). Acetic acid and ammonium acetate were obtained from Sigma-Aldrich (St. Louis, MO, USA). The eicosanoid standards were as follows: 14,15-EET-d11, 5(S)HETE-d8, LTB~4~-d4, PGE~2~-d4, PGD~2~-d4, and AA-d8 (Cayman Chemical, Ann Arbor, MI, USA). A Strata-x 33-µm polymerized solid reverse-phase extraction column (cat \# 8B-S100-UBJ) was purchased from Phenomenex (Torrance, CA, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-ethylenediaminetetraacetic acid (EDTA) were purchased from HyClone Laboratories Inc. (Logan, UT, USA). Escherichia coli LPS and Griess reagent were obtained from Sigma Chemical Co. (St Louis, MO, USA).

4.2. Cell Culture and LPS Treatment {#sec4dot2-ijms-17-00508}
-----------------------------------

Murine macrophage RAW264.7 cells (KCLB 40071; Korean Cell Line Bank, Seoul, Korea) were cultured in DMEM containing 10% heat-inactivated FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere with 5% CO~2~ at 37 °C. Cells were seeded in a 100-mm Petri dish, cultured for 24 h, and incubated for a further 18 h after treatment with 100 µL LPS (0, 1, 10, 100, and 1000 ng/mL). Cell pellets were collected from each culture dish and the cells were enumerated using a hemocytometer. Finally, 1 × 10^7^ cells were used in the analyses.

4.3. Nitric Oxide (NO) and Enzyme-Linked Immunosorbent Assays (ELISAs) Analyses {#sec4dot3-ijms-17-00508}
-------------------------------------------------------------------------------

NO concentrations in the culture supernatants were determined using a spectrophotometric assay based on the Griess reaction. A calibration curve was constructed using known concentrations (0--100 µM) of sodium nitrite. Levels of proinflammatory cytokines such as TNF-α and IL-6 were analyzed using commercial ELISA kits (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions.

4.4. Sample Preparation {#sec4dot4-ijms-17-00508}
-----------------------

A simple solid-phase extraction method was applied for the extraction of eicosanoids \[[@B25-ijms-17-00508]\]. Cells were resuspended in 1 mL of 10% methanol in water (*v*/*v*) and sonicated for 5 min. Samples were then spiked with 10 ng of deuterated internal standards. Eicosanoids were extracted using Strata-x 33-µm polymerized solid reverse-phase extraction columns. Briefly, the columns were activated with 3.5 mL of 100% methanol followed by 3.5 mL of water for equilibration. After loading the samples, the columns were washed with 3.5 mL of 10% methanol in water to remove non-specific-binding metabolites. Eicosanoids were eluted into 1 mL methanol. The eluted samples were dried using a Speed-Vac concentrator (Labconco, Kansas City, MO, USA) and resuspended in 90 µL of Solvent A, as described below. The samples were stored at −80 °C until analysis.

4.5. UPLC-MS/MS Conditions {#sec4dot5-ijms-17-00508}
--------------------------

The UPLC analyses were performed on a Waters ACQUITY UPLC instrument (Waters Corp., Milford, MA, USA). The temperature of the column oven and autosampler were set at 40 and 4 °C, respectively. An Acquity BEH300 C18 column (2.1 × 150 mm ID; 1.7 µm; Waters Corp.) was used for the separation of eicosanoids. Solvent A consisted of water/acetonitrile/acetic acid (70:30:0.02; *v*/*v*/*v*) and solvent B of acetonitrile/isopropyl alcohol (50:50, *v*/*v*). The gradient elution program was as follows: 0--1 min, B 0%; 1--3 min, B 0%--25%; 3--11 min, B 25%--45%; 11--13 min, B 45%--60%; 13--18 min, B 60%--75%; 18--18.5 min, B 75%--90%; 18.5--20 min, B 90%; and 20--21 min, B 90%--0%. The column was equilibrated with 0% Solvent B for 4 min prior to analysis of the next sample. The total run time was 25 min for each analysis. The flow rate was 0.5 mL/min and the injection volume was 40 µL for each run.

For the MS analyses, an ABI/Sciex (Foster City, CA, USA) 5500 QTRAP hybrid, triple quadrupole, linear ion trap mass spectrometer equipped with a Turbo V ion source, together with the Analyst 1.5.1 software package (ABI/Sciex, Foster City, CA, USA), was used. Ultra-pure nitrogen gas was used as the collision gas for eicosanoids. The typical operating source conditions for the analysis of eicosanoids in negative ion ESI mode were optimized using deuterated standards as follows: curtain gas (CUR) = 10 psi, GS1 = 30 psi, GS2 = 30 psi, ionspray voltage (IS) = −4500 V, collision gas setting (CAD) = high, Temp = 525 °C, Ihe = on, entrance potential (EP) = −10 V, and collision cell exit potential (CXP) = −10 V.

4.6. Validation Study {#sec4dot6-ijms-17-00508}
---------------------

External standard curves were established from the analysis of mixed eicosanoid standards at 16 different concentrations (0.1, 0.3, 0.6, 1, 3, 6, 10, 30, 60, 100, 300, 600, 1000, 3000, 6000, and 10,000 pg). In the case of 14,15 EET-d11, seven different concentrations (1000, 3000, 6000, 10,000, 30,000, 60,000, and 100,000 pg) were applied. The LOD, LOQ, linear ranges, and correlation (*R*^2^) values were determined by the external standard curve. The RSDs (%) of the relative RTs and the relative peak areas were estimated after six replicate analyses of 3000 pg of each standard.

4.7. Data Processing and Statistical Analysis {#sec4dot7-ijms-17-00508}
---------------------------------------------

LC-MS data were obtained using the Analyst 1.5.1 software package (ABI/Sciex, Foster City, CA, USA). Eicosanoid peaks were assigned by comparisons of retention times with those of the internal standards. The Skyline software package (MacCoss Laboratory, University of Washington, Seattle, WA, USA) was used as an in-house database to determine the peak area of each assigned lipid from replicate raw data. The extracted peak areas of lipid peaks were normalized to the appropriate internal standard \[[@B42-ijms-17-00508]\]. Hierarchical clustering of the quantified eicosanoids and PCA analyses was performed on the MetaboAnalyst web site \[[@B43-ijms-17-00508]\].
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![Chemical structures of typical eicosanoids: prostaglandin E~2~ (PGE~2~), leukotriene B~4~ (LTB~4~), 5-hydroxy-eicosatetraenoic acid (5(S)-HETE), and 5,6-epoxy-eicosatrienoic acid (5,6 EET).](ijms-17-00508-g001){#ijms-17-00508-f001}

![Morphological changes in RAW264.7 cells treated with 0, 1, 10, 100, and 1000 ng/mL lipopolysaccharide (LPS). The morphology of RAW 264.7 cells was visualized by optical microscopy (400×).](ijms-17-00508-g002){#ijms-17-00508-f002}

![(**A**) nitric oxide (NO); (**B**) tumor necrosis factor-α (TNF-α); and (**C**) interleukin-6 (IL-6) production by RAW264.7 cells treated with 0, 1, 10, 100, and 1000 ng/mL LPS. \*\*\* *p* value \< 0.001.](ijms-17-00508-g003){#ijms-17-00508-f003}

![Merged multiple reaction monitoring data of six standards---PGE~2~-d4, PGD~2~-d4, LTB~4~-d4, 14,15-EET-d11, 5(S)-HETE-d8, and AA-d8.](ijms-17-00508-g004){#ijms-17-00508-f004}

![Principal component analysis (PCA) score plot of RAW264.7 cells treated with 0, 1, 10, 100, and 1000 ng/mL LPS.](ijms-17-00508-g005){#ijms-17-00508-f005}

![Hierarchical clustering of 79 eicosanoid datasets from RAW264.7 cells treated with 0, 1, 10, 100, and 1000 ng/mL LPS.](ijms-17-00508-g006){#ijms-17-00508-f006}

![The eicosanoid synthesis pathway from arachidonic acid (AA) and eicosanoid levels in RAW264.7 cells as a function of LPS concentration (0, 1, 10, 100, and 1000 ng/mL). COX, cyclooxygenase; LOX, lipoxygenase; PG, prostaglandin; HETE, hydroxyeicosatetraenoic acid.](ijms-17-00508-g007){#ijms-17-00508-f007}

ijms-17-00508-t001_Table 1

###### 

Optimized multiple-reaction monitoring (MRM) conditions for eicosanoid standards.

  Compounds                             Abbreviation    Ion Mode   MRM Transitions   DP    CE    
  ------------------------------------- --------------- ---------- ----------------- ----- ----- -----
  Prostaglandin E~2~-d4                 PGE~2~-d4       Negative   355               275   −50   −25
  Prostaglandin D~2~-d4                 PGD~2~-d4       Negative   355               275   −50   −25
  Leukotriene B~4~-d4                   LTB~4~-d4       Negative   339               197   −70   −22
  14,15 Epoxy-eicosatrienoic acid-d11   14,15 EET-d11   Negative   330               202   −50   −15
  5-Hydroxy-eicosatetraenoic acid-d8    5(S)-HETE-d8    Negative   327               116   −50   −20
  Arachidonic acid-d8                   AA-d8           Negative   311               267   −80   −20

Q1, precursor *m*/*z*; Q3, product *m*/*z*; DP, Declustering potential; CE, Collision energy.

ijms-17-00508-t002_Table 2

###### 

Validation of the eicosanoid profiling method based on UPLC-MS/MS and the LOD and LOQ of each compound.

  Eicosanoids     RT (min)   RSD (*n* = 6) (%)   Correlation (*R*^2^)   Linear Range (pg)   LOD (pg)          LOQ (pg)   
  --------------- ---------- ------------------- ---------------------- ------------------- ----------------- ---------- --------
  PGE~2~-d4       8.06       0.25                2.85                   0.9978              30--10,000        3          30
  PGD~2~-d4       8.43       0                   4.44                   0.9982              30--10,000        3          30
  LTB~4~-d4       12.77      0.20                5.39                   0.9969              100--10,000       60         100
  14,15 EET-d11   17.70      0                   6.08                   0.9964              10,000--100,000   3000       10,000
  5(S)-HETE-d8    17.85      0                   5.01                   0.9972              30--10,000        6          30
  AA-d8           21.53      0                   7.84                   0.9959              3--6000           0.1        3

UPLC-MS/MS, Ultra performance liquid chromatography coupled to tandem mass spectrometry; LOD, The limit of detection; LOQ, The limit of quantification; RT, Retention time; RSD, Relative standard deviation.

ijms-17-00508-t003_Table 3

###### 

Eicosanoids identified in RAW264.7 cells.

  No.   Compound Name                                                    Abbreviation                 MRM Transitions   DP    CE     RT (min)   IS     Alteration by LPS Treatment   
  ----- ---------------------------------------------------------------- ---------------------------- ----------------- ----- ------ ---------- ------ ----------------------------- ------
  1     12S-hydroxy-heptadecatrienoic acid                               12-HHT                       279               163   −30    −30        14.3   5(S)HETE-d8                   Up
  2     13-hydroxy-g-octadecatrienoic acid                               13-HOTre-g                   293               193   −70    −20        15.5   5(S)HETE-d8                   Up
  3     9-hydroxy-octadecadienoic acid                                   9-HODE                       295               171   −60    −25        16.6   5(S)HETE-d8                   Up
  4     13-hydroxy-octadecadienoic acid                                  13-HODE                      295               195   −60    −25        16.3   5(S)HETE-d8                   --
  5     9,10-hydroxy-octadecadienoic acid                                9,10-diHOME                  313               201   −60    −30        14.2   5(S)HETE-d8                   --
  6     12,13-hydroxy-octadecadienoic acid                               12,13-diHOME                 313               183   −60    −30        13.5   5(S)HETE-d8                   --
  7     9-hydroxy-eicosapentaenoic acid                                  9-HEPE                       317               149   −75    −20        15.7   5(S)HETE-d8                   Up
  8     5-hydroxy-eicosapentaenoic acid                                  5-HEPE                       317               115   −40    −17        16.6   5(S)HETE-d8                   Down
  9     15-hydroxy-eicosapentaenoic acid                                 15-HEPE                      317               219   −60    −20        15.5   5(S)HETE-d8                   Up
  10    8-hydroxy-eicosapentaenoic acid                                  8-HEPE                       317               127   −70    −25        15.5   5(S)HETE-d8                   --
  11    11-hydroxy-eicosapentaenoic acid                                 11-HEPE                      317               121   −70    −24        15.7   5(S)HETE-d8                   Up
  12    12-hydroxy-eicosapentaenoic acid                                 12-HEPE                      317               179   −70    −20        15.9   5(S)HETE-d8                   --
  13    18-hydroxy-eicosapentaenoic acid                                 18-HEPE                      317               215   −60    −20        15.1   5(S)HETE-d8                   --
  14    11-hydroxy-eicosatetraenoic acid                                 11-HETE                      319               167   −60    −20        17.1   5(S)HETE-d8                   Up
  15    9-hydroxy-eicosatetraenoic acid                                  9-HETE                       319               151   −60    −20        17.0   5(S)HETE-d8                   Up
  16    5-hydroxy-eicosatetraenoic acid                                  5-HETE                       319               115   −60    −20        17.9   5(S)HETE-d8                   Down
  17    8-hydroxy-eicosatetraenoic acid                                  8-HETE                       319               155   −60    −20        17.3   5(S)HETE-d8                   --
  18    15-hydroxy-eicosatetraenoic acid                                 15-HETE                      319               219   −50    −15        16.7   5(S)HETE-d8                   Up
  19    12-hydroxy-eicosatetraenoic acid                                 12-HETE                      319               179   −60    −20        17.3   5(S)HETE-d8                   Up
  20    18-hydroxy-eicosatetraenoic acid                                 18-HETE                      319               261   −80    −25        15.9   5(S)HETE-d8                   --
  21    17-hydroxy-eicosatetraenoic acid                                 17-HETE                      319               247   −80    −25        15.9   5(S)HETE-d8                   --
  22    16-hydroxy-eicosatetraenoic acid                                 16-HETE                      319               189   −80    −25        16.0   5(S)HETE-d8                   --
  23    5-hydroxy-eicosatrienoic acid                                    5-HETrE                      321               115   −70    −19        19.1   5(S)HETE-d8                   Down
  24    15-hydroxy-eicosatrienoic acid                                   15-HETrE                     321               221   −70    −21        17.4   5(S)HETE-d8                   Up
  25    5,6-dihydroxy-eicosatrienoic acid                                5,6-DHET                     337               145   −75    −25        16.5   5(S)HETE-d8                   Down
  26    8,9-dihydroxy-eicosatrienoic acid                                8,9-DHET                     337               127   −60    −30        15.5   5(S)HETE-d8                   --
  27    11,12-dihydroxy-eicosatrienoic acid                              11,12-DHET                   337               167   −60    −25        15.8   5(S)HETE-d8                   Up
  28    8-hydroxy-docosahexaenoic acid                                   8-HDoHE                      343               109   −70    −20        17.5   5(S)HETE-d8                   --
  29    7-hydroxy-docosahexaenoic acid                                   7-HDoHE                      343               141   −60    −18        17.3   5(S)HETE-d8                   --
  30    4-hydroxy-docosahexaenoic acid                                   4-HDoHE                      343               101   −70    −17        18.2   5(S)HETE-d8                   --
  31    10-hydroxy-docosahexaenoic acid                                  10-HDoHE                     343               181   −60    −17        16.9   5(S)HETE-d8                   --
  32    11-hydroxy-docosahexaenoic acid                                  11-HDoHE                     343               149   −60    −19        17.0   5(S)HETE-d8                   Up
  33    13-hydroxy-docosahexaenoic acid                                  13-HDoHE                     343               221   −60    −17        16.7   5(S)HETE-d8                   Up
  34    16-hydroxy-docosahexaenoic acid                                  16-HDoHE                     343               233   −75    −19        16.5   5(S)HETE-d8                   Up
  35    20-hydroxy-docosahexaenoic acid                                  20-HDoHE                     343               241   −60    −20        16.3   5(S)HETE-d8                   --
  36    17-hydroxy-docosahexaenoic acid                                  17-HDoHE                     343               245   −60    −20        16.5   5(S)HETE-d8                   Up
  37    14-hydroxy-docosahexaenoic acid                                  14-HDoHE                     343               205   −60    −18        16.7   5(S)HETE-d8                   --
  38    Arachidonic acid                                                 AA                           303               259   −80    −20        21.6   AA-d8                         Down
  39    Eicosapentaenoic acid                                            EPA                          301               257   −65    −15        20.4   AA-d8                         --
  40    Adrenic acid                                                     ADA                          331               287   −80    −20        22.3   AA-d8                         --
  41    Dohexacosaenoic acid                                             DHA                          327               283   −95    −20        21.3   AA-d8                         --
  42    13-oxo-octadecadienoic acid                                      13-oxoODE                    293               113   −70    −30        16.6   14,15 EET-d11                 --
  43    9,10-epoxy-octadecenoic acid                                     9,10-EpOME                   295               171   −60    −25        18.4   14,15 EET-d11                 --
  44    12,13-epoxy-octadecenoic acid                                    12,13-EpOME                  295               195   −60    −25        18.1   14,15 EET-d11                 --
  45    5-5-oxo-eicosatetraenoic acid                                    5-oxoETE                     317               203   −40    −25        18.3   14,15 EET-d11                 --
  46    15-5-oxo-eicosatetraenoic acid                                   15-oxoETE                    317               113   −40    −25        16.7   14,15 EET-d11                 --
  47    11,12-epoxy-eicosatrienoic acid                                  11,12-EET                    319               167   −60    −20        18.6   14,15 EET-d11                 Down
  48    14,15-epoxy-eicosatrienoic acid                                  14,15-EET                    319               219   −50    −15        18.1   14,15 EET-d11                 --
  49    5,6-epoxy-eicosatrienoic acid                                    5,6-EET                      319               191   −30    −20        18.8   14,15 EET-d11                 Down
  50    15-oxo-eicosadienoic acid                                        15-oxoEDE                    321               113   −100   −32        18.1   14,15 EET-d11                 Up
  51    Hepoxilin B~3~                                                   HXB~3~                       335               183   −40    −20        15.5   14,15 EET-d11                 --
  52    19,20-epoxy Docosapentaenoic acid                                19,20-EpDPE                  343               241   −60    −20        17.6   14,15 EET-d11                 --
  53    Lipoxin B~4~                                                     LXB~4~                       351               221   −80    −25        8.4    LTB~4~-d4                     Up
  54    20-carboxy-Leukotriene B~4~                                      20cooh LTB~4~                365               195   −60    −25        6.4    LTB~4~-d4                     --
  55    15-deoxy-Prostaglandin A~2~ or 15-deoxy-Δ12,14-PGJ~2~            15d-PGA~2~ or 15d-PGJ~2~     315               271   −50    −15        15.2   PGE~2~-d4                     Up
  56    Tetranor-Prostanglin F Metabolite                                tetranor-PGFM                329               293   −40    −25        3.1    PGE~2~-d4                     --
  57    Prostaglandin A~2~ or Prostaglandin B~2~ or Prostaglandin J~2~   PGA~2~ or PGB~2~ or PGJ~2~   333               271   −30    −20        10.5   PGE~2~-d4                     Up
  58    15-deoxy-Δ12,14-PGD~2~                                           15d-PGD~2~                   333               271   −30    −20        12.8   PGE~2~-d4                     Up
  59    Prostaglandin D~3~                                               PGD~3~                       349               269   −55    −25        7.4    PGE~2~-d4                     Up
  60    Prostaglandin E~3~                                               PGE~3~                       349               269   −55    −25        7.1    PGE~2~-d4                     Up
  61    15-keto-Prostaglandin E~2~                                       15k PGE~2~                   349               113   −35    −30        8.3    PGE~2~-d4                     --
  62    Prostaglandin K~2~                                               PGK~2~                       349               205   −50    −30        8.3    PGE~2~-d4                     Up
  63    15-keto-Prostaglandin F~2~                                       15k PGF~2~                   351               113   −40    −35        8.6    PGE~2~-d4                     Up
  64    Prostaglandin E~2~                                               PGE~2~                       351               271   −50    -25        8.1    PGE~2~-d4                     Up
  65    Prostaglandin D~2~                                               PGD~2~                       351               271   −50    −25        8.4    PGE~2~-d4                     Up
  66    13,14-dihydro-15-keto Prostaglandin E~2~                         dhk PGE~2~                   351               207   −40    −25        8.4    PGE~2~-d4                     Up
  67    13,14-dihydro-15-keto Prostaglandin D~2~                         dhk PGD~2~                   351               207   −40    −25        9.3    PGE~2~-d4                     Up
  68    Prostaglandin F~2α~                                              PGF~2α~                      353               193   −50    −30        8.5    PGE~2~-d4                     Up
  69    15-keto-Prostaglandin F~1α~                                      15k PGF~1α~                  353               113   −50    −35        3.1    PGE~2~-d4                     --
  70    11β-13,14-dihydro-15-keto-Prostaglandin F~2α~                    11β dhk PGF~2α~              353               113   −50    −35        9.3    PGE~2~-d4                     Up
  71    Prostaglandin E~1~                                               PGE~1~                       353               273   −55    −25        8.1    PGE~2~-d4                     Up
  72    Prostaglandin D~1~                                               PGD~1~                       353               273   −55    −25        8.5    PGE~2~-d4                     Up
  73    Prostaglandin F~1α~                                              PGF~1α~                      355               293   −75    −30        8.2    PGE~2~-d4                     Up
  74    13,14-dihydro-Prostaglandin F~2α~                                dh PGF~2α~                   355               275   −40    −25        8.9    PGE~2~-d4                     --
  75    Dihomo-Prostaglandin J~2~                                        Dihomo-PGJ~2~                361               299   −55    −25        13.0   PGE~2~-d4                     Up
  76    Dihomo-15-deoxy-Prostaglandin J~2~                               Dihomo-15d PGJ~2~            361               299   −55    −25        14.4   PGE~2~-d4                     Up
  77    Thromboxane B~3~                                                 TXB~3~                       367               169   −50    −25        6.4    PGE~2~-d4                     --
  78    Dihomo-Prostaglandin F~2α~                                       Dihomo-PGF~2α~               381               221   −75    −35        10.0   PGE~2~-d4                     Up
  79    Dihomo-Prostaglandin D~2~                                        Dihomo-PGD~2~                379               299   −65    −30        10.4   PGE~2~-d4                     Up

[^1]: These authors contributed equally to this work.
